Additive effect

Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Additive effect, Postcholecystectomy syndrome, CRi, JAK, University, ASH, Disease, MLL, Patient, QT, Division, SMPA, Cancer, Acute leukemia, Growth, MD Anderson Cancer Center, Society, Relapse, Blood, Pharmaceutical industry, Leukemia

CAMBRIDGE, Mass., Dec. 11, 2023 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced new data from the ongoing Phase 1/2 first-in-human study of DSP-5336, in patients with relapsed or refractory acute leukemia, presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis.1,2,3 

Key Points: 
  • In the ongoing study, patients are continuing to dose escalate and are now at therapeutic levels.
  • Preliminary results presented at ASH 2023 included four evaluable patients treated with DSP-5336 200 mg twice-daily, three of whom showed objective responses.
  • Inhibition of the menin-MLL protein interaction may be able to reverse the leukemogenic activity of MLL fusion proteins and may be a future therapeutic option for acute leukemia."
  • We look forward to continuing the study of DSP-5336 as a monotherapy and to exploring additional combination studies."

NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING

Retrieved on: 
Friday, December 1, 2023
Empowerment, Status epilepticus, Brain, Research, Annual general meeting, Additive effect, SAN, Food, American Epilepsy Society, Effectiveness, Panic, Literature, Plasma, Risk, Comparison, AAS, CIV, Diazepam, FDA, Prompt, Pharmacokinetics, Caregiver, Epilepsy, Human, DZP, Rat, Systematic review, AES, Pharmaceutical industry, Drug, Vaccine, Dietary supplement, Seizure, Male, Patient, Female, Safety

SAN DIEGO, Dec. 1, 2023 /PRNewswire/ -- Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023. Two of the presentations include new analyses of data from the completed long-term phase 3 open-label, repeat-dose safety study of diazepam nasal spray (VALTOCO®) for the treatment of seizure clusters in patients with epilepsy aged ≥6 years, evaluating timing, safety, and effectiveness of treatment. A third presentation focuses on the further assessment of diazepam in a novel preclinical model dosing strategy with potential application for further in vivo studies. Additional presentations explore the concept of anticipatory anxiety of seizures (AAS) through literature review, comparison of treated and untreated seizure clusters in a retrospective analysis from the SeizureTracker® database, and the short-term impact of seizures beyond the seizure itself.

Key Points: 
  • "Our ultimate goal is to improve health outcomes by addressing gaps in seizure cluster treatment and control," said Adrian L. Rabinowicz, M.D., Chief Medical Officer.
  • "The data presented this year at the AES annual meeting demonstrate our ongoing commitment to improving the future of epilepsy care by advancing meaningful, patient-focused treatment outcomes for people with epilepsy."
  • "Neurelis is at the forefront of epilepsy research, as evidenced by the wide breadth of data presented at this year's AES annual meeting," said Enrique Carrazana, M.D., Neurelis Senior Vice President, Strategic Initiatives.
  • Results showed sustained and measurable DZP levels in plasma and brain, which were similar to levels observed in humans.

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
EGFR, Research, NSCLC, Fatigue, Epithelioid hemangioendothelioma, TEAD, Diarrhea, Physician, Hippopotamus, Weight gain, Meningioma, Liver, Quarter, Wind, Additive effect, Nausea, NF2, Quality of life, Growth, Disease, Caregiver, Clinical trial, Neoplasm, TEAD1, Biology, DLT, Cancer, Partnership, Collaboration, Mesothelioma, Liver failure, Nephrotoxicity, Blood, Pain, Patient, VGLL4, TAZ, EHE, Therapeutic index, Proteinuria, Pharmaceutical industry, Vaccine, Cryptocurrency, Pionýr

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.

Key Points: 
  • The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
  • “This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
  • Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
  • Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.

Global Healthy Living Foundation to Present Pioneering Patient-Centered Research at ACR Convergence 2023

Retrieved on: 
Thursday, November 9, 2023
Biometrics, Telemedicine, Virtual Medicine, Pharmaceutical, General Health, Health, Wearables, Mobile Technology, Technology, Other Health, Online, Rheumatism, American College, Hospital, Treatment, Face, Doctor of Philosophy, Medicine, Disease, Efficacy, COVID-19, Overalls, Culture, PRO, Pain, Medical Affairs Bureau, Gold, MPH, Impact, Additive effect, RA, American College of Rheumatology, Data management, Exercise, Patient, ACR, Plant, Rehabilitation, MD, Motivation, Mindfulness, Quality of life, Longitudinal study, Research, Osteoporosis, DSM-IV codes, Guideline, Rheumatoid arthritis, Role, TNF inhibitor, Pros, Conjoint analysis, Jaki, Poster, Ageing, WEAR, Pharmaceutical industry, Medical device, Medical imaging, Nursing, Dietary supplement, Diet, Rheumatology, Fatigue, Flare, Epidemiology, Arthritis

The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).

Key Points: 
  • The Global Healthy Living Foundation and its digital, arthritis patient centered research registry, formerly ArthritisPower, will collaboratively present eight scientific abstracts and five patient perspective posters at the American College of Rheumatology Convergence 2023 (Philadelphia, PA, November 10-15, 2023).
  • Collectively, GHLF researchers will focus on innovative approaches to remote therapeutic monitoring, patient engagement, and personalized care in rheumatic and musculoskeletal diseases.
  • This study offers key insights on innovative disease tracking methods, including those that can happen outside traditional clinical settings, particularly for diseases like rheumatoid arthritis (RA).
  • GHLF anticipates engaging with fellow organizations and professionals at ACR Convergence to share their year-long accomplishments in rheumatic disease research.

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Retrieved on: 
Saturday, November 4, 2023
Patient, CST, OPTIC, Adverum Biotechnologies, AMD, Data, AAO, Injection, Maintenance, Inflammation, Additive effect, Learning, IVT, American Academy, American Academy of Ophthalmology, Annual general meeting, Safety, Visual acuity, Anti-VEGF, Medical imaging, Birth control, Pharmaceutical industry, Dietary supplement

A summary of previously announced aflibercept protein levels from the LUNA study was also presented.

Key Points: 
  • A summary of previously announced aflibercept protein levels from the LUNA study was also presented.
  • “These efforts are now supported by the most mature dataset in wet AMD IVT gene therapy, with the OPTIC safety and efficacy data now sustained out to 3 years.
  • We are particularly encouraged by the continuous and consistent aflibercept protein levels observed at up to 4.5 years post-treatment.
  • Taken together, the efficacy and safety at the 2E11 dose in the OPTIC trial underscore Ixo-vec's potential as a promising treatment option for wet AMD patients addressing real-world unmet needs.

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Retrieved on: 
Wednesday, October 4, 2023
ABOS, Neuron, Additive effect, Interview, Clinical trial, Research, Eligibility, Human voice, ARIA, Poster, Synapse, AD, Study, Safety, Complex, Pharmaceutical industry, Fine chemical, Acumen

INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations.

Key Points: 
  • INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations.
  • Decades of research have shown that soluble AβOs are a highly toxic form of Aβ, based on their propensity to bind to neurons, disrupt synapses and contribute to tau hyper-phosphorylation.
  • ACU193 is the first clinical-stage antibody designed to selectively bind AβOs, inhibiting their ability to disrupt synaptic function, while potentially offering improved safety and clinical benefit over existing amyloid-directed therapies.
  • “Following Acumen’s announcement of positive topline results from the Phase 1, first-in-human trial of ACU193, we are excited to present more extensive insights into the trial data and novel target engagement of ACU193,” said Daniel O’Connell, President and Chief Executive Officer of Acumen.

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Retrieved on: 
Tuesday, September 5, 2023
Additive effect, ACRV, Neoplasm, Proteomics, Medicine, AP3, IC50, WEE1, Investigational New Drug, Patient, PKMYT1, Drug discovery, Therapy, IND, Medical imaging, Pharmaceutical industry

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced a novel, internally developed clinical candidate, ACR-2316, a dual WEE1 and PKMYT1 inhibitor. The company plans to prioritize Investigational New Drug (IND) enabling studies for ACR-2316 to be ready for IND submission by the fourth quarter of 2024.

Key Points: 
  • The company plans to prioritize Investigational New Drug (IND) enabling studies for ACR-2316 to be ready for IND submission by the fourth quarter of 2024.
  • The compound is designed for high selectivity towards WEE1 and PKMYT1, exhibiting single-digit nM IC50 potency in a carefully predetermined ratio to ensure strong single agent anti-tumor activity, as demonstrated in tumor-bearing rodent models and other preclinical analyses.
  • “The preclinical data we have generated thus far is consistent with potential clinical advantages and possible differentiation compared to current single inhibitors of WEE1 and PKMYT1, both critically important cell cycle regulators with demonstrated clinical activity,” said Erick Gamelin, M.D., Ph.D., chief medical officer of Acrivon.
  • “We are particularly encouraged by its compelling target selectivity and preclinical potency profile.

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

Retrieved on: 
Wednesday, August 16, 2023
Moyamoya disease, Additive effect, Prevalence, Angina, Calcium channel, Heart failure with preserved ejection fraction, Professor, Patient, Hemodynamics, Physician, MRCP, Pharmaceutical industry

BOSTON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing innovative therapies designed to improve patient symptoms and function by enhancing cellular energetics, today announced that it has completed enrollment in the IMPROVE-ISCHEMIA Phase 2 placebo-controlled clinical trial of the investigational therapy, ninerafaxstat, in patients with stable angina. Imbria expects to report topline results from this trial in the fourth quarter of 2023.

Key Points: 
  • Imbria expects to report topline results from this trial in the fourth quarter of 2023.
  • “The randomized, placebo-controlled IMPROVE-ISCHEMIA trial will provide detailed insights into the anti-ischemic effects of ninerafaxstat in symptomatic patients with chronic coronary syndromes, including the burden of angina," said Juhani Knuuti, M.D., Ph.D., Professor and Director of Turku PET Centre in Turku, Finland and chief investigator of the IMPROVE-ISCHEMIA trial.
  • This could give physicians and patients an additional option to control angina symptoms without adversely impacting hemodynamics,” said Jai Patel, MRCP (U.K.), chief medical officer of Imbria.
  • “We look forward to sharing topline data from the trial in the fourth quarter of this year.”
    Imbria currently has two additional ongoing Phase 2 clinical trials with ninerafaxstat: IMPROVE-HCM, a randomized, placebo-controlled clinical trial in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) with topline data expected in the fourth quarter of 2023, and IMPROVE-DiCE, an open label clinical trial, which is currently enrolling patients with cardiometabolic heart failure with preserved ejection fraction (HFpEF) with interim data also expected in the fourth quarter of 2023.

MedStar Health Celebrates 40th Anniversary of MedSTAR Transport Air Medical Service

Retrieved on: 
Wednesday, June 28, 2023
Devon Hall, Heart, Pentagon, Assistive technology, Additive effect, Accident, Atmosphere, Intra-aortic balloon pump, Professional, COVID-19, ECMO, Health, Finger, Ambulance, Multimedia, MedSTAR, BSN, MedStar Health, Hospital, Publication, MedStar Washington Hospital Center, Patient, MedStar National Rehabilitation Hospital, MedStar Union Memorial Hospital, RN, Nursing care plan, Growth, Hand, Environment, Mid-Atlantic (United States), APRV, Safety, Injury, Nursing, Online shopping, MD

COLUMBIA, Md., June 28, 2023 /PRNewswire/ -- MedStar Health is honoring the groundbreaking and enduring legacy of MedSTAR Transport, which first launched its life-saving air medevac services 40 years ago.

Key Points: 
  • "It's actually a good example of how MedSTAR Transport is more than just ambulances and helicopters," Dr. Drass said.
  • "As the medical director for our air and ground teams, I'm thrilled to be a part of this critical service that continues to grow with the full support of MedStar Health to help patients receive the care they need when they need it," said MedSTAR Transport Medical Director J. Matthew Sasser, MD .
  • "Long before I started working for MedStar Health, I called on MedSTAR Transport often to transport critical patients who needed a higher level of care than was offered at my hospitals.
  • In addition to MedStar Washington Hospital Center and area community hospitals, MedStar Health hospitals with helipads where MedSTAR Transport can land and take off with patients include:
    Transferring patients proved critically important at the height of the COVID-19 pandemic, as MedStar Health relied on MedSTAR Transport — which saw a 40% increase in transport volume — to distribute severely ill patients across the health system.